Univariate logistic regression for patients undergoing bilateral salpingo-oophorectomy (n=234) versus ovarian suppression (n=282) for ovarian ablation
|
Variables | Levels | OR | 95% CI lower bounds | 95% CI upper bounds | p value |
| Age at diagnosis | As one year increase | 1.051 | 1.021 | 1.082 | <0.001 |
| Year of diagnosis | 2011 vs 2010 | 1.075 | 0.589 | 1.960 | 0.082 |
| 2012 vs 2010 | 0.832 | 0.459 | 1.508 | ||
| 2013 vs 2010 | 0.581 | 0.329 | 1.025 | ||
| 2014 vs 2010 | 0.597 | 0.348 | 1.023 | ||
| Family history (15 unknown) | Yes vs no | 1.034 | 0.724 | 1.477 | 0.852 |
| Live children | Yes vs no | 1.362 | 0.910 | 2.038 | 0.133 |
| Histology | Lobular no ductal vs ductal no lobular | 0.927 | 0.534 | 1.609 | 0.176 |
| Lobular and ductal vs ductal no lobular | 2.522 | 1.192 | 5.334 | ||
| Inflammatory vs ductal no lobular | 0.630 | 0.057 | 7.007 | ||
| Other vs ductal no lobular | 0.841 | 0.139 | 5.083 | ||
| Grade (32 unknown) | G2 vs G1 | 0.639 | 0.210 | 1.941 | 0.286 |
| G3 vs G1 | 0.892 | 0.307 | 2.598 | ||
| LN pos exact (2 unknown) | Yes vs No | 0.901 | 0.636 | 1.275 | 0.556 |
| Stage (59 unknown) | II vs I | 1.130 | 0.745 | 1.713 | 0.777 |
| III vs I | 0.962 | 0.590 | 1.568 | ||
| Chemotherapy | Yes vs no | 1.179 | 0.806 | 1.727 | 0.396 |
| HER-2 targeted | Trastuzumab vs none | 1.587 | 0.902 | 2.790 | 0.076 |
| Trastuzumab+other vs none | 1.851 | 0.929 | 3.691 |
The OR is modeled for BSO yes, as OR>1 means more likely to get BSO, OR<1 less likely to get BSO. Unknown=number of patients in analysis who did not have documentation for this variable.
Bold p values represent p values of significance.
BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; LN, lymph node; OS, ovarian suppression.